Department of Hematology, University Hospital Basel, Basel, Switzerland.
Bone Marrow Transplant. 2013 Feb;48(2):220-5. doi: 10.1038/bmt.2012.119. Epub 2012 Jul 9.
The number of allogeneic hematopoietic SCTs performed globally each year continues to increase, paralleled by an increased demand for donors of therapeutic cells. Donor characteristics and collection procedures have undergone major changes during recent decades, and further changes are foreseen. Information on short- and long-term donor outcomes is of crucial importance to ensure maximal donor safety and availability. Current data, predominantly from unrelated donors, give reliable information on the frequent early events associated with donation-most of them of mild-to-moderate intensity. Information on the type and relative risk of serious adverse reactions is more limited. Moreover, only few data exist on long-term donor outcome. On the basis of this need, recommendations for a minimum data set for prospective donor follow-up were developed in a workshop with the participation of an international group of investigators actively involved in allogeneic stem cell donation under the auspices of and approved by the Worldwide Network for Blood and Marrow Transplantation. Establishment of a standardized global follow-up for both, related and unrelated, donors will enable monitoring of the short- and long-term safety profiles of hematopoietic cell donation and form a solid basis for future donor selection and counseling.
全球每年进行的异基因造血干细胞移植数量持续增加,随之而来的是对治疗性细胞供体的需求增加。在最近几十年中,供体特征和采集程序发生了重大变化,预计还会有进一步的变化。供体短期和长期结局的信息对于确保最大程度的供体安全性和可用性至关重要。目前的数据主要来自无关供体,可提供与捐赠相关的频繁早期事件的可靠信息,其中大多数为轻度至中度强度。关于严重不良反应的类型和相对风险的信息则更为有限。此外,关于长期供体结局的数据也很少。有鉴于此,在一个由国际血液和骨髓移植网络主办并经其批准的研讨会中,一组积极参与异基因干细胞捐献的国际研究人员参与制定了前瞻性供体随访的最低数据集建议。为相关和无关供体建立标准化的全球随访将能够监测造血细胞捐献的短期和长期安全性,并为未来的供体选择和咨询提供坚实的基础。